Proactive Investors - Run By Investors For Investors

ANGLE technology used in cutting-edge research featured in science journal Nature

Parstortix was central to the analysis carried out by a team at the University of Basel, in Switzerland
cancer cells
Scientists have come closer to understanding why cancer spreads in the way it does

ANGLE PLC (LON:AGL), the med-tech firm at the forefront of cancer research, said its liquid biopsy system has been used in research featured in the prestigious science journal Nature.

Parstortix was central to the analysis carried out by a team at the University of Basel, in Switzerland, which highlighted the role of immune cells assigned to protect the body from the disease in actually promoting the spread of cancer - a process called metastasis.

READ: ANGLE on track to complete key Parsortix study in current quarter

The research published in Nature identified a subset of circulating tumour cell clusters using ANGLE's technology that was demonstrated to be associated with greatly increased metastatic ability.

Understanding the role of the patient’s own immune system in aiding cancer spread opens the potential for the development of new therapies that impede the process.

"Research into CTC clusters using the Parsortix system has the potential to change the way that cancer is treated,” said ANGLE founder and chief executive Andrew Newland.

“The publication of the University of Basel's research in Nature on CTC-neutrophil clusters, following the previous publication in Cell, is a tremendous achievement for Basel, one of ANGLE's leading customers.

“We are delighted that the harvesting of CTC clusters, using the Parsortix system, is a key element in the drive to block the process of cancer metastasis that is responsible for over 90% of deaths from cancer."

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use